Watkins Katherine E, Ober Allison J, Lamp Karen, Lind Mimi, Setodji Claude, Osilla Karen Chan, Hunter Sarah B, McCullough Colleen M, Becker Kirsten, Iyiewuare Praise O, Diamant Allison, Heinzerling Keith, Pincus Harold Alan
RAND Corporation, Santa Monica, California.
Venice Family Clinic, Los Angeles, California.
JAMA Intern Med. 2017 Oct 1;177(10):1480-1488. doi: 10.1001/jamainternmed.2017.3947.
Primary care offers an important and underutilized setting to deliver treatment for opioid and/or alcohol use disorders (OAUD). Collaborative care (CC) is effective but has not been tested for OAUD.
To determine whether CC for OAUD improves delivery of evidence-based treatments for OAUD and increases self-reported abstinence compared with usual primary care.
DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of 377 primary care patients with OAUD was conducted in 2 clinics in a federally qualified health center. Participants were recruited from June 3, 2014, to January 15, 2016, and followed for 6 months.
Of the 377 participants, 187 were randomized to CC and 190 were randomized to usual care; 77 (20.4%) of the participants were female, of whom 39 (20.9%) were randomized to CC and 38 (20.0%) were randomized to UC. The mean (SD) age of all respondents at baseline was 42 (12.0) years, 41(11.7) years for the CC group, and 43 (12.2) yearsfor the UC group. Collaborative care was a system-level intervention, designed to increase the delivery of either a 6-session brief psychotherapy treatment and/or medication-assisted treatment with either sublingual buprenorphine/naloxone for opioid use disorders or long-acting injectable naltrexone for alcohol use disorders. Usual care participants were told that the clinic provided OAUD treatment and given a number for appointment scheduling and list of community referrals.
The primary outcomes were use of any evidence-based treatment for OAUD and self-reported abstinence from opioids or alcohol at 6 months. The secondary outcomes included the Healthcare Effectiveness Data and Information Set (HEDIS) initiation and engagement measures, abstinence from other substances, heavy drinking, health-related quality of life, and consequences from OAUD.
At 6 months, the proportion of participants who received any OAUD treatment was higher in the CC group compared with usual care (73 [39.0%] vs 32 [16.8%]; logistic model adjusted OR, 3.97; 95% CI, 2.32-6.79; P < .001). A higher proportion of CC participants reported abstinence from opioids or alcohol at 6 months (32.8% vs 22.3%); after linear probability model adjustment for covariates (β = 0.12; 95% CI, 0.01-0.23; P = .03). In secondary analyses, the proportion meeting the HEDIS initiation and engagement measures was also higher among CC participants (initiation, 31.6% vs 13.7%; adjusted OR, 3.54; 95% CI, 2.02-6.20; P < .001; engagement, 15.5% vs 4.2%; adjusted OR, 5.89; 95% CI, 2.43-14.32; P < .001) as was abstinence from opioids, cocaine, methamphetamines, marijuana, and any alcohol (26.3% vs 15.6%; effect estimate, β = 0.13; 95% CI, 0.03-0.23; P = .01).
Among adults with OAUD in primary care, the SUMMIT collaborative care intervention resulted in significantly more access to treatment and abstinence from alcohol and drugs at 6 months, than usual care.
clinicaltrials.gov Identifier: NCT01810159.
初级保健为阿片类药物和/或酒精使用障碍(OAUD)提供了重要但未得到充分利用的治疗环境。协作护理(CC)是有效的,但尚未针对OAUD进行测试。
确定与常规初级保健相比,OAUD的CC是否能改善基于证据的OAUD治疗的提供情况,并增加自我报告的戒酒率。
设计、设置和参与者:在一家联邦合格健康中心的2家诊所对377名患有OAUD的初级保健患者进行了一项随机临床试验。参与者于2014年6月3日至2016年1月15日招募,并随访6个月。
在377名参与者中,187名被随机分配到CC组,190名被随机分配到常规护理组;77名(20.4%)参与者为女性,其中39名(20.9%)被随机分配到CC组,38名(20.0%)被随机分配到UC组。所有受访者在基线时的平均(标准差)年龄为42(12.0)岁,CC组为41(11.7)岁,UC组为43(12.2)岁。协作护理是一种系统层面的干预措施,旨在增加提供为期6节的简短心理治疗和/或药物辅助治疗,对于阿片类药物使用障碍使用舌下丁丙诺啡/纳洛酮,对于酒精使用障碍使用长效注射用纳曲酮。常规护理参与者被告知诊所有提供OAUD治疗,并给予预约安排号码和社区转诊清单。
主要结局是使用任何基于证据的OAUD治疗方法以及在6个月时自我报告的阿片类药物或酒精戒断情况。次要结局包括医疗保健有效性数据和信息集(HEDIS)启动和参与指标、其他物质的戒断情况、大量饮酒、与健康相关的生活质量以及OAUD的后果。
在6个月时,CC组接受任何OAUD治疗的参与者比例高于常规护理组(73名[39.0%]对32名[16.8%];逻辑模型调整后的OR为3.97;95%CI为2.32 - 6.79;P <.001)。更高比例的CC参与者在6个月时报告阿片类药物或酒精戒断(32.8%对22.3%);在对协变量进行线性概率模型调整后(β = 0.12;95%CI为0.01 - 0.23;P = 0.03)。在次要分析中,CC参与者中达到HEDIS启动和参与指标的比例也更高(启动,31.6%对13.7%;调整后的OR为3.54;95%CI为2.02 - 6.20;P <.001;参与,15.5%对4.2%;调整后的OR为5.89;95%CI为2.43 - 14.32;P <.001),阿片类药物、可卡因、甲基苯丙胺、大麻和任何酒精的戒断情况也是如此(26.3%对15.6%;效应估计值β = 0.13;95%CI为0.03 - 0.23;P = 0.01)。
在初级保健中患有OAUD的成年人中,SUMMIT协作护理干预在6个月时导致获得治疗的机会显著增加,且酒精和药物戒断情况优于常规护理。
clinicaltrials.gov标识符:NCT01810159。